Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 28;2(1):vdaa053. doi: 10.1093/noajnl/vdaa053

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Influence of molecular markers and prior therapy on GPR133 expression within the GBM cohort. (A–D) IDH mutation, MGMT promoter methylation, TP53 immunohistochemical signal, and EGFR amplification had no effect on GPR133 expression within the core of GBM tumors (Mann–Whitney test; ns, P > .05). (E) No difference in GPR133 tumor core expression was found among RTK I, RTK II, and mesenchymal subtypes of gliomas (Kruskal–Wallis test; ns, P = .9876). (Fi and ii) There was no difference between newly diagnosed and previously treated recurrent GBM within the tumor core (i) or infiltrative edge (ii) (Mann–Whitney test; ns, P > .05).